Research programme: T-cell receptor therapeutics - ImmuVen

Drug Profile

Research programme: T-cell receptor therapeutics - ImmuVen

Alternative Names: IMV-0123

Latest Information Update: 02 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Illinois at Urbana-Champaign
  • Developer ImmuVen
  • Class Cell therapies; Proteins
  • Mechanism of Action T-cell receptor antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Methicillin-resistant Staphylococcus aureus infections

Most Recent Events

  • 02 May 2012 ImmuVen is awarded a phase II Small Business Innovation Research grant from the US NIAID to continue development of its lead therapeutic IMV0123, for the treatment of MRSA and MSSA infections
  • 06 Jan 2011 Research programme: T-cell receptor therapeutics - ImmuVen is available for licensing as of 04 Jan 2011. http://www.immuven.com
  • 04 Jan 2011 Preclinical trials in Cancer diagnosis in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top